Page 154 - Read Online

Müller. Neuroimmunol Neuroinflammation 2018;5:23 I http://dx.doi.org/10.20517/2347-8659.2018.27 Page 3 of 3

DECLARATIONS
Authors’ contributions
Müller T contributed solely to the paper.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
The author declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Larner AJ. Correlation or limits of agreement? Applying the Bland-Altman approach to the comparison of cognitive screening
instruments. Dement Geriatr Cogn Disord 2016;42:247-54.
2. Kleine-Borgmann J, Bingel U. Nocebo effects: neurobiological mechanisms and strategies for prevention and optimizing treatment. Int
Rev Neurobiol 2018;138:271-83.
3. Ren Y, Xu F. How patients be counseled on adverse drug reactions: avoiding the nocebo effect. Res Social Adm Pharm 2018; doi:
10.1016/j.sapharm.2018.04.007.
4. Beran RG, Hegazi Y, Schwartz RS, Cordato DJ. Rebound exacerbation multiple sclerosis following cessation of oral treatment. Mult
Scler Relat Disord 2013;2:252-5.
5. Igra MS, Paling D, Wattjes MP, Connolly DJA, Hoggard N. Multiple sclerosis update: use of MRI for early diagnosis, disease
monitoring and assessment of treatment related complications. Br J Radiol 2017;90:20160721.
6. Mulero P, Neri MJ, Rodriguez M, Arenillas JF, Téllez N. Immune reconstitution inflammatory syndrome and natalizumab - is it possible
before removing the drug? Mult Scler Relat Disord 2014; 3:659-61.